1
|
Villadiego J, García-Swinburn R, García-González D, Lebrón-Galán R, Murcia-Belmonte V, García-Roldán E, Suárez-Luna N, Nombela C, Marchena M, de Castro F, Toledo-Aral JJ. Extracellular matrix protein anosmin-1 overexpression alters dopaminergic phenotype in the CNS and the PNS with no pathogenic consequences in a MPTP model of Parkinson's disease. Brain Struct Funct 2023; 228:907-920. [PMID: 36995433 PMCID: PMC10147818 DOI: 10.1007/s00429-023-02631-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Accepted: 03/15/2023] [Indexed: 03/31/2023]
Abstract
The development and survival of dopaminergic neurons are influenced by the fibroblast growth factor (FGF) pathway. Anosmin-1 (A1) is an extracellular matrix protein that acts as a major regulator of this signaling pathway, controlling FGF diffusion, and receptor interaction and shuttling. In particular, previous work showed that A1 overexpression results in more dopaminergic neurons in the olfactory bulb. Prompted by those intriguing results, in this study, we investigated the effects of A1 overexpression on different populations of catecholaminergic neurons in the central (CNS) and the peripheral nervous systems (PNS). We found that A1 overexpression increases the number of dopaminergic substantia nigra pars compacta (SNpc) neurons and alters the striosome/matrix organization of the striatum. Interestingly, these numerical and morphological changes in the nigrostriatal pathway of A1-mice did not confer an altered susceptibility to experimental MPTP-parkinsonism with respect to wild-type controls. Moreover, the study of the effects of A1 overexpression was extended to different dopaminergic tissues associated with the PNS, detecting a significant reduction in the number of dopaminergic chemosensitive carotid body glomus cells in A1-mice. Overall, our work shows that A1 regulates the development and survival of dopaminergic neurons in different nuclei of the mammalian nervous system.
Collapse
Affiliation(s)
- Javier Villadiego
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío-CSIC-Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013, Seville, Spain
- Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009, Sevilla, Spain
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
| | - Roberto García-Swinburn
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío-CSIC-Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013, Seville, Spain
- Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009, Sevilla, Spain
| | - Diego García-González
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío-CSIC-Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013, Seville, Spain
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, 45071, Toledo, Spain
| | - Rafael Lebrón-Galán
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, 45071, Toledo, Spain
| | - Verónica Murcia-Belmonte
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, 45071, Toledo, Spain
- Instituto de Neurociencias, UMH-CSIC, Sant Joan d´Alacant, 03550, Alicante, Spain
| | - Ernesto García-Roldán
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío-CSIC-Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013, Seville, Spain
- Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009, Sevilla, Spain
- Servicio de Neurología y Neurofisiología Clínica, Hospital Universitario Virgen del Rocío, 41013, Sevilla, Spain
| | - Nela Suárez-Luna
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío-CSIC-Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013, Seville, Spain
- Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009, Sevilla, Spain
| | - Cristina Nombela
- Departamento de Psicología Biológica y de la Salud, Universidad Autónoma de Madrid, 28049, Madrid, Spain
| | - Miguel Marchena
- Grupo de Neurobiología del Desarrollo-GNDe, Instituto Cajal-CSIC, Avenida Doctor Arce 37, 28002, Madrid, Spain
- Departamento de Medicina, Universidad Europea de Madrid-UEM, Villaviciosa de Odón, 28670, Madrid, Spain
| | - Fernando de Castro
- Grupo de Neurobiología del Desarrollo-GNDe, Hospital Nacional de Parapléjicos, 45071, Toledo, Spain.
- Grupo de Neurobiología del Desarrollo-GNDe, Instituto Cajal-CSIC, Avenida Doctor Arce 37, 28002, Madrid, Spain.
| | - Juan José Toledo-Aral
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío-CSIC-Universidad de Sevilla, Avda. Manuel Siurot s/n, 41013, Seville, Spain.
- Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, 41009, Sevilla, Spain.
- Centro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
| |
Collapse
|
2
|
García-Miranda P, Morón-Civanto FJ, Martínez-Olivo MDM, Suárez-Luna N, Ramírez-Lorca R, Lebrato-Hernández L, Lamas-Pérez R, Navarro G, Abril-Jaramillo J, García-Sánchez MI, Casado-Chocán JL, Uclés-Sánchez AJ, Romera M, Echevarría M, Díaz-Sánchez M. Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders. Int J Mol Sci 2019; 20:ijms20225810. [PMID: 31752329 PMCID: PMC6887710 DOI: 10.3390/ijms20225810] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Revised: 11/11/2019] [Accepted: 11/17/2019] [Indexed: 12/15/2022] Open
Abstract
The detection of IgG aquaporin-4 antibodies in the serum of patients with Neuromyelitis optica (NMO) has dramatically improved the diagnosis of this disease and its distinction from multiple sclerosis. Recently, a group of patients have been described who have an NMO spectrum disorder (NMOsd) and who are seronegative for AQP4 antibodies but positive for IgG aquaporin-1 (AQP1) or myelin oligodendrocyte glycoprotein (MOG) antibodies. The purpose of this study was to determine whether AQP1 and MOG could be considered new biomarkers of this disease; and if point mutations in the gDNA of AQP4, AQP1 and MOG genes could be associated with the etiology of NMOsd. We evaluated the diagnostic capability of ELISA and cell-based assays (CBA), and analyzed their reliability, specificity, and sensitivity in detecting antibodies against these three proteins. The results showed that both assays can recognize these antigen proteins under appropriate conditions, but only anti-AQP4 antibodies, and not AQP1 or MOG, appears to be a clear biomarker for NMOsd. CBA is the best method for detecting these antibodies; and serum levels of AQP4 antibodies do not correlate with the progression of this disease. So far, the sequencing analysis has not revealed a genetic basis for the etiology of NMOsd, but a more extensive analysis is required before definitive conclusions can be drawn.
Collapse
Affiliation(s)
- Pablo García-Miranda
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain; (P.G.-M.); (F.J.M.-C.); (M.d.M.M.-O.); (N.S.-L.); (R.R.-L.)
| | - Francisco J. Morón-Civanto
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain; (P.G.-M.); (F.J.M.-C.); (M.d.M.M.-O.); (N.S.-L.); (R.R.-L.)
| | - Maria del Mar Martínez-Olivo
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain; (P.G.-M.); (F.J.M.-C.); (M.d.M.M.-O.); (N.S.-L.); (R.R.-L.)
| | - Nela Suárez-Luna
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain; (P.G.-M.); (F.J.M.-C.); (M.d.M.M.-O.); (N.S.-L.); (R.R.-L.)
| | - Reposo Ramírez-Lorca
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain; (P.G.-M.); (F.J.M.-C.); (M.d.M.M.-O.); (N.S.-L.); (R.R.-L.)
| | - Lucía Lebrato-Hernández
- Unidad de Gestión Clínica de Neurociencias, Servicio de Neurología del Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (L.L.-H.); (R.L.-P.); (J.L.C.-C.); (A.J.U.-S.)
| | - Raquel Lamas-Pérez
- Unidad de Gestión Clínica de Neurociencias, Servicio de Neurología del Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (L.L.-H.); (R.L.-P.); (J.L.C.-C.); (A.J.U.-S.)
| | - Guillermo Navarro
- Servicio de Neurología del Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain; (G.N.); (J.A.-J.); (M.I.G.-S.)
| | - Javier Abril-Jaramillo
- Servicio de Neurología del Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain; (G.N.); (J.A.-J.); (M.I.G.-S.)
| | - Maria Isabel García-Sánchez
- Servicio de Neurología del Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain; (G.N.); (J.A.-J.); (M.I.G.-S.)
| | - José Luis Casado-Chocán
- Unidad de Gestión Clínica de Neurociencias, Servicio de Neurología del Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (L.L.-H.); (R.L.-P.); (J.L.C.-C.); (A.J.U.-S.)
| | - Antonio José Uclés-Sánchez
- Unidad de Gestión Clínica de Neurociencias, Servicio de Neurología del Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (L.L.-H.); (R.L.-P.); (J.L.C.-C.); (A.J.U.-S.)
| | - Mercedes Romera
- Servicio de Neurología del Hospital Universitario Virgen de Valme, 41014 Sevilla, Spain;
| | - Miriam Echevarría
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41013 Seville, Spain; (P.G.-M.); (F.J.M.-C.); (M.d.M.M.-O.); (N.S.-L.); (R.R.-L.)
- Correspondence: (M.E.); (M.D.-S.); Tel.: +34-955-923036 (M.E.); +34-955-012593 (M.D.-S.)
| | - María Díaz-Sánchez
- Unidad de Gestión Clínica de Neurociencias, Servicio de Neurología del Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain; (L.L.-H.); (R.L.-P.); (J.L.C.-C.); (A.J.U.-S.)
- Correspondence: (M.E.); (M.D.-S.); Tel.: +34-955-923036 (M.E.); +34-955-012593 (M.D.-S.)
| |
Collapse
|
3
|
Trillo-Contreras JL, Ramírez-Lorca R, Hiraldo-González L, Sánchez-Gomar I, Galán-Cobo A, Suárez-Luna N, Sánchez de Rojas-de Pedro E, Toledo-Aral JJ, Villadiego J, Echevarría M. Combined effects of aquaporin-4 and hypoxia produce age-related hydrocephalus. Biochim Biophys Acta Mol Basis Dis 2018; 1864:3515-3526. [PMID: 30293570 DOI: 10.1016/j.bbadis.2018.08.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 08/01/2018] [Accepted: 08/05/2018] [Indexed: 10/28/2022]
Abstract
Aquaporin-4, present in ependymal cells, in glia limiting and abundantly in pericapillary astrocyte foot processes, and aquaporin-1, expressed in choroid plexus epithelial cells, play an important role in cerebrospinal fluid production and may be involved in the pathophysiology of age-dependent hydrocephalus. The finding that brain aquaporins expression is regulated by low oxygen tension led us to investigate how hypoxia and elevated levels of cerebral aquaporins may result in an increase in cerebrospinal fluid production that could be associated with a hydrocephalic condition. Here we have explored, in young and aged mice exposed to hypoxia, whether aquaporin-4 and aquaporin-1 participate in the development of age-related hydrocephalus. Choroid plexus, striatum, cortex and ependymal tissue were analyzed separately both for mRNA and protein levels of aquaporins. Furthermore, parameters such as total ventricular volume, intraventricular pressure, cerebrospinal fluid outflow rate, ventricular compliance and cognitive function were studied in wild type, aquaporin-1 and aquaporin-4 knock-out animals subjected to hypoxia or normoxia. Our data demonstrate that hypoxia is involved in the development of age-related hydrocephalus by a process that depends on aquaporin-4 channels as a main route for cerebrospinal fluid movement. Significant increases in aquaporin-4 expression that occur over the course of animal aging, together with a reduced cerebrospinal fluid outflow rate and ventricular compliance, contribute to produce more severe hydrocephalus related to hypoxic events in aged mice, with a notable impairment in cognitive function. These results indicate that physiological events and/or pathological conditions presenting with cerebral hypoxia/ischemia contribute to the development of chronic adult hydrocephalus.
Collapse
Affiliation(s)
- José Luis Trillo-Contreras
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain
| | - Reposo Ramírez-Lorca
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain
| | - Laura Hiraldo-González
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain
| | - Ismael Sánchez-Gomar
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain
| | - Ana Galán-Cobo
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain
| | - Nela Suárez-Luna
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain
| | - Eva Sánchez de Rojas-de Pedro
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain
| | - Juan José Toledo-Aral
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain
| | - Javier Villadiego
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Spain.
| | - Miriam Echevarría
- Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital. (HUVR)/Spanish National Research Council (CSIC)/University of Seville, Seville 41013, Spain; Department of Physiology and Biophysics, University of Seville, Seville 41009, Spain.
| |
Collapse
|
4
|
Villadiego J, Romo-Madero S, García-Swinburn R, Suárez-Luna N, Bermejo-Navas A, Echevarría M, Toledo-Aral JJ. Long-term immunosuppression for CNS mouse xenotransplantation: Effects on nigrostriatal neurodegeneration and neuroprotective carotid body cell therapy. Xenotransplantation 2018; 25:e12410. [PMID: 29932254 DOI: 10.1111/xen.12410] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2018] [Revised: 04/09/2018] [Accepted: 05/02/2018] [Indexed: 02/01/2023]
Abstract
BACKGROUND The use of long-term immunosuppressive treatments on neural transplantation has been controversial during the last decades. Although nowadays there is a consensus about the necessity of maintaining a permanent state of immunosuppression to preserve the survival of cerebral grafts, little is known about the effects that chronic immunosuppression produces both on the neurodegenerative process and on transplants function. METHODS Here, we establish a new immunosuppressive protocol, based on the discontinuous administration of CsA (15 mg/kg; s.c.) and prednisone (20 mg/kg; s.c.), to produce long-term immunosuppression in mice. Using this treatment, we analyse the effects that long-term immunosuppression induces in a chronic 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) model of parkinsonism and on the neuroprotective and neurorestorative anti-parkinsonian actions exerted by rat carotid body (CB) xenografts. RESULTS This protocol preserves the survival of rat CB xenotransplants maintaining the general wellness of the grafted mice. Although permanent immunosuppression does not prevent the MPTP-induced cell death of nigral neurons and the consequent degeneration of dopaminergic striatal innervation, allowing for its use as Parkinson's disease (PD) model, it reduces the microglial activation and slightly declines the striatal damage. Moreover, we reported that chronic administration of immunosuppressant drugs does not alter the neuroprotective and restorative anti-parkinsonian actions of rat CB xenografts into parkinsonian mice. CONCLUSIONS This new immunosuppressive protocol provides a new murine model to assay the long-term effects of cerebral xenografts and offer a pharmacological alternative to the commonly used genetic immunodeficient mice, allowing the use of genetically modified mice as hosts. In addition, it will permit the experimental analysis of the effects produced by human CB xenografts in the chronic PD murine model, with the final aim of using CB allografts as an option of cell therapy in PD patients.
Collapse
Affiliation(s)
- Javier Villadiego
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain.,Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Sonia Romo-Madero
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain
| | - Roberto García-Swinburn
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain
| | - Nela Suárez-Luna
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain
| | - Alfonso Bermejo-Navas
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain
| | - Miriam Echevarría
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain
| | - Juan J Toledo-Aral
- Instituto de Biomedicina de Sevilla-IBiS, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.,Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Sevilla, Spain.,Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
| |
Collapse
|
5
|
Galán-Cobo A, Arellano-Orden E, Sánchez Silva R, López-Campos JL, Gutiérrez Rivera C, Gómez Izquierdo L, Suárez-Luna N, Molina-Molina M, Rodríguez Portal JA, Echevarría M. The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target. Front Mol Biosci 2018; 5:43. [PMID: 29774214 PMCID: PMC5943501 DOI: 10.3389/fmolb.2018.00043] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 04/13/2018] [Indexed: 01/30/2023] Open
Abstract
Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease.
Collapse
Affiliation(s)
- Ana Galán-Cobo
- Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain
| | - Elena Arellano-Orden
- Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain
| | - Rocío Sánchez Silva
- Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain
| | - José Luis López-Campos
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain.,Centro de Investigación Biomédica en Red sobre Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - César Gutiérrez Rivera
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain
| | | | - Nela Suárez-Luna
- Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain
| | - María Molina-Molina
- Centro de Investigación Biomédica en Red sobre Enfermedades Respiratorias (CIBERES), Madrid, Spain.,Laboratorio de Neumologia Experimental, Servicio de Neumologia, Institut d'Investigació Biomédica de Bellvitge, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - José A Rodríguez Portal
- Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, Spain
| | - Miriam Echevarría
- Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, Spain
| |
Collapse
|
6
|
Muñoz-Manchado AB, Villadiego J, Romo-Madero S, Suárez-Luna N, Bermejo-Navas A, Rodríguez-Gómez JA, Garrido-Gil P, Labandeira-García JL, Echevarría M, López-Barneo J, Toledo-Aral JJ. Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. J Neurochem 2015; 136:373-87. [DOI: 10.1111/jnc.13409] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 09/14/2015] [Accepted: 10/11/2015] [Indexed: 12/21/2022]
Affiliation(s)
- Ana B. Muñoz-Manchado
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - Javier Villadiego
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - Sonia Romo-Madero
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - Nela Suárez-Luna
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - Alfonso Bermejo-Navas
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - José A. Rodríguez-Gómez
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - Pablo Garrido-Gil
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
- Departamento de Ciencias Morfológicas; Universidad de Santiago de Compostela; CIMUS; Instituto de Investigación Sanitaria (IDIS); Santiago de Compostela Spain
| | - José L. Labandeira-García
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
- Departamento de Ciencias Morfológicas; Universidad de Santiago de Compostela; CIMUS; Instituto de Investigación Sanitaria (IDIS); Santiago de Compostela Spain
| | - Miriam Echevarría
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - José López-Barneo
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| | - Juan J. Toledo-Aral
- Instituto de Biomedicina de Sevilla-IBiS; HUVR/Universidad de Sevilla/CSIC; Sevilla Spain
- Departamento de Fisiología Médica y Biofísica; Universidad de Sevilla; Sevilla Spain
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED); Spain
| |
Collapse
|
7
|
Muñoz-Manchado AB, Villadiego J, Suárez-Luna N, Bermejo-Navas A, Garrido-Gil P, Labandeira-García JL, Echevarría M, López-Barneo J, Toledo-Aral JJ. Neuroprotective and reparative effects of carotid body grafts in a chronic MPTP model of Parkinson's disease. Neurobiol Aging 2013; 34:902-15. [DOI: 10.1016/j.neurobiolaging.2012.06.001] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2011] [Revised: 03/19/2012] [Accepted: 06/01/2012] [Indexed: 12/28/2022]
|